Delivery rates following IVF treatment, using two recombinant FSH preparations for ovarian stimulation

被引:8
作者
Harlin, J [1 ]
Aanesen, A [1 ]
Csemiczky, G [1 ]
Wramsby, H [1 ]
Fried, G [1 ]
机构
[1] Karolinska Hosp, Dept Women & Child Hlth, Div Obstet & Gynaecol, Reprod Med Ctr, S-17176 Stockholm, Sweden
关键词
delivery rates; ovarian stimulation; recombinant FSH;
D O I
10.1093/humrep/17.2.304
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
BACKGROUND: A prospective, semi-randomized, open, clinical study was conducted to compare ovarian response, pregnancy outcome and delivery rates using two recombinant FSH preparations (Gonal-F(R) and Puregon(R)) for IVF. METHODS: We analysed stimulation parameters and outcome data in 812 initiated treatment cycles where 292 women used Gonal-F and 200 used Puregon. Embryo transfer was carried out in 676 cycles. In the two preparation groups we also compared 170 women previously treated with FSH for IVF with 266 previously untreated. RESULTS: The pregnancy rate with Gonal-F was 26% and with Puregon 28%. Delivery rates were identical, 22%. Clinical pregnancy and delivery rates per cycle with embryo transfer in earlier untreated women were 29.0 and 24.0%, whereas in previously treated women they were 23.5 and 18.8% respectively. After repeated cycles, delivery frequencies consecutively decreased, independent of the FSH preparation used. CONCLUSION: Gonal-F and Puregon seem to be equally potent in achieving follicular development and equally effective, in terms of delivery rates, for use in an IVF programme. Repeated cycles resulted in equally large consecutive decreases in delivery rates, regardless of preparation choice, but were considered worthwhile for up to three stimulation cycles in selected patients.
引用
收藏
页码:304 / 309
页数:6
相关论文
共 20 条
[1]  
Baird DT, 2000, HUM REPROD, V15, P723
[2]   Clinical efficacy of recombinant gonadotrophins [J].
Balen, AH ;
Hayden, CJ ;
Rutherford, AJ .
HUMAN REPRODUCTION, 1999, 14 (06) :1411-1417
[3]   Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F®) versus highly purified urinary FSH (Metrodin HP®):: results of a randomized comparative study in women undergoing assisted reproductive techniques [J].
Bergh, C ;
Howles, CM ;
Borg, K ;
Hamberger, L ;
Josefsson, B ;
Nilsson, L ;
Wikland, M .
HUMAN REPRODUCTION, 1997, 12 (10) :2133-2139
[4]   Recombinant follicle stimulating hormone [J].
Bergh, C .
HUMAN REPRODUCTION, 1999, 14 (06) :1418-1419
[5]   A comparison of the efficacy and tolerability of two recombinant human follicle-stimulating hormone preparations in patients undergoing in vitro fertilization-embryo transfer [J].
Brinsden, P ;
Akagbosu, F ;
Gibbons, LM ;
Lancaster, S ;
Gourdon, D ;
Engrand, P ;
Loumaye, E .
FERTILITY AND STERILITY, 2000, 73 (01) :114-116
[6]   OVARIAN-FUNCTION IN RELATION TO THE OUTCOME OF IN-VITRO FERTILIZATION (IVF) TREATMENT IN REGULARLY MENSTRUATING WOMEN WITH TUBAL INFERTILITY [J].
CSEMICZKY, G ;
WRAMSBY, H ;
LANDGREN, BM .
JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 1995, 12 (10) :683-688
[7]   Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction [J].
Daya, S ;
Gunby, J .
HUMAN REPRODUCTION, 1999, 14 (09) :2207-2215
[8]   CLINICAL OUTCOME OF A PILOT EFFICACY STUDY ON RECOMBINANT HUMAN FOLLICLE-STIMULATING-HORMONE (ORG-32489) COMBINED WITH VARIOUS GONADOTROPIN-RELEASING-HORMONE AGONIST REGIMENS [J].
DEVROEY, P ;
MANNAERTS, B ;
SMITZ, J ;
BENNINK, HC ;
VANSTEIRTEGHEM, A .
HUMAN REPRODUCTION, 1994, 9 (06) :1064-1069
[9]   Recombinant follicle stimulating hormone in in-vitro fertilization treatment - clinical experience with follitropin alpha and follitropin beta [J].
Harlin, J ;
Csemiczky, G ;
Wramsby, H ;
Fried, G .
HUMAN REPRODUCTION, 2000, 15 (02) :239-244
[10]   The age-related decline in female fecundity: A quantitative controlled study of implanting capacity and survival of individual embryos after in vitro fertilization [J].
Hull, MGR ;
Fleming, CF ;
Hughes, AO ;
McDermott, A .
FERTILITY AND STERILITY, 1996, 65 (04) :783-790